{
    "title": "110_hr3368",
    "content": "The Act may be cited as the \"Pulmonary Hypertension Research and Education Act of 2007\". The Congress finds that pulmonary hypertension is a serious and often fatal condition where blood pressure in the lungs rises to dangerously high levels. The walls of the arteries thickening and constricting, causing the right side of the heart to pump harder, leading to enlargement and potential failure. Federal investment in pulmonary hypertension research must be expanded to find a cure or effective treatment, and collaboration among research centers should be increased. Pulmonary hypertension is difficult to diagnose and is rarely detected in routine medical examinations. Pulmonary hypertension is challenging to diagnose and often goes undetected in routine medical exams. New diagnostic standards have improved detection rates. In advanced stages, patients experience severe limitations in physical activity and may become completely bedridden. In 1981, the National Heart, Lung, and Blood Institute established the first pulmonary hypertension patient registry, following 194 people over several years. Research on the disease is ongoing due to the lack of a full understanding of its cause and the absence of a cure. Research on pulmonary hypertension has been ongoing for years, with a focus on understanding the cause and progression of the illness. Studies are looking into immunologic and genetic factors, agents that narrow pulmonary blood vessels, and factors that promote cell growth and scar tissue formation in vessel walls. Treatments for pulmonary hypertension have advanced, with six FDA-approved medications available and more in trials. Research on pulmonary hypertension has led to advancements in treatments, with six FDA-approved medications available and more in trials. However, not all medications are effective for all patients, and treatments have significant negative side effects. Lung transplantation is considered a last resort treatment. The number of physicians treating pulmonary hypertension and patients receiving treatment has grown exponentially, necessitating increased medical education. The number of physicians treating pulmonary hypertension and patients receiving treatment has grown exponentially over the past decade, leading to the need for increased medical education. In 2001, there were 100 identified physicians treating pulmonary hypertension and 3,000 patients receiving treatment. By 2006, there were an estimated 3,000 physicians and 30,000 patients. Treatment options now include easy-to-administer oral therapies, but effective management remains complicated. In December 2006, the National Heart, Lung, and Blood Institute hosted a landmark meeting of pulmonary hypertension researchers and clinicians from around the world, with over 500 attendees. Communication among researchers was highlighted as crucial for future advancements in managing pulmonary hypertension. During a meeting organized by the National Heart, Lung, and Blood Institute, over 500 individuals emphasized the importance of communication among researchers for advancements in managing pulmonary hypertension. The Public Health Service Act is amended to expand pulmonary hypertension research and training through the creation of a Pulmonary Hypertension Clinical Research Network. The Director of the Institute will establish a Pulmonary Hypertension Clinical Research Network to conduct clinical trials and collaborate on new treatment approaches for pulmonary hypertension. The Pulmonary Hypertension Clinical Research Network will evaluate new treatment approaches for pulmonary hypertension and consist of 15 clinical centers, an institute project scientist, a data and coordinating center, a data and safety monitoring board, and a steering committee. The Pulmonary Hypertension Clinical Research Network includes a data and safety monitoring board, a steering committee, and an independent protocol review committee appointed by the Director. The steering committee determines clinical trials, sets subject selection standards, develops protocols, and analyzes results. The steering committee of the Pulmonary Hypertension Clinical Research Network determines specific clinical trials, establishes subject selection standards, develops protocols, and analyzes and publishes trial results. Clinical trials may include combination therapies, new drug avenues targeting cellular defects, use of endothelial progenitor cells, and discovery of treatment effects. The Institute is responsible for managing and supporting the Pulmonary Hypertension Clinical Research Network, including monitoring trial progress and subject recruitment. The Institute project scientist oversees subject recruitment, trial progress, conflict disclosure, and fiscal management of the network. An institute grants management specialist assists in fiscal management. The Director appoints the Chair of the steering committee, members of the protocol review committee, and the data safety monitoring board. Additionally, a pulmonary hypertension preceptorship and training program must be established within one year. The Director appoints members of various committees and establishes a Pulmonary Hypertension Preceptorship and Training Program within a year. The Director establishes a national Pulmonary Hypertension Preceptorship and Training Program to educate medical professionals in clinical settings and increase the number of physicians trained to diagnose, treat, and manage pulmonary hypertension. The program will include regional training sites to facilitate training by experienced specialists. The Pulmonary Hypertension Preceptorship and Training Program aims to educate medical professionals in diagnosing, treating, and managing pulmonary hypertension. It includes establishing regional training sites across the United States at recognized health centers, hospitals, or medical practices. Each site will have a designated contact person, with grant funds allocated for their stipend. The program includes regional training sites with designated contacts receiving stipends. The nonprofit entity will recruit health professionals and establish program guidelines. Authorization of appropriations is provided for program implementation. The nonprofit entity will recruit health professionals and work with regional training sites to establish model guidelines for the program. Authorization of appropriations is provided for program implementation. Increasing public awareness of pulmonary hypertension. The Secretary of Health and Human Services will develop and share information on pulmonary hypertension, including basic information, prevalence, related diseases, early diagnosis importance, and treatment options. This information will be disseminated through a national non-profit entity with expertise in pulmonary hypertension. The Secretary of Health and Human Services will disseminate information on pulmonary hypertension treatment options through a national non-profit entity. Appropriations are authorized for fiscal years 2009 through 2012. The Secretary of Health and Human Services will disseminate information on pulmonary hypertension treatment options through a national non-profit entity. The Secretary of Health and Human Services will develop and disseminate information on pulmonary hypertension to healthcare providers, including warning signs, early diagnosis importance, diagnostic criteria, and FDA-approved therapies. This information will be shared with cardiologists, pulmonologists, rheumatologists, primary care physicians, pediatricians, and nurse practitioners. The Secretary of Health and Human Services will disseminate information on pulmonary hypertension to healthcare providers through a national non-profit entity with expertise in the field. Appropriations are authorized for fiscal years 2009 through 2012. The Comptroller General of the United States will conduct a study on Medicare and Medicaid coverage standards for individuals with pulmonary hypertension, detailing coverage for FDA-approved therapies. A report on the findings must be submitted to Congress within six months of the Act's enactment."
}